NCT03276468已完成2 期
A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas
The Lymphoma Academic Research Organisation25 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2018年2月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 136
- 试验地点
- 25
- 主要终点
- FL and DLBCL cohorts : Overall Metabolic Response Rate (OMRR) at the end of induction
研究概览
简要总结
This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts:
- relapsed/refractory follicular lymphoma (FL) patients
- relapsed/refractory aggressive (DLBCL) lymphoma patients
- relapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically documented CD20-positive follicular lymphoma (WHO grade 1, 2, or 3a) patients for cohort 1
- •Patients with either histologically documented CD20-positive Diffuse large-cell lymphoma (including transformations of low-grade lymphoma into DLBCL) or follicular lymphoma CD20+ grade 3b, or primary cutaneous DLBCL leg type, or primary mediastinal (thymic) large B-cell lymphoma, or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, or unclassifiable B-cell lymphoma with features intermediate between DLBCL and Hodgkin (WHO classification) for cohort 2
- •Patients with relapsed/refractory indolent lymphoma (marginal zone (MZL) or measurable mucosa-associated lymphoid tissue (MALT) lymphoma) for cohort 3
- •Relapsed/refractory NHL after ≥1 prior R-containing regimen with no curative option
- •Aged 18 years or more with no upper age limit
- •Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
- •Bi-dimensionally measurable disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan, or Positron Emission Tomography (PET) scan without IV contrast at diagnosis with at least one hypermetabolic lesion
- •Signed written informed consent
- •Life expectancy ≥ 3 months
- •Females of childbearing potential (FCBP) must agree to use one reliable form of contraception or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 18 months after discontinuation of all study treatments
- •Male patients and their partner (FCBP) must agree to use two reliable forms of contraception (condom for males and hormonal method for partners) during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 18 months after discontinuation of all study treatments
- •Patient covered by any social security system
排除标准
- •Lymphocytic lymphoma (LL), waldenström macroglobulinemia, unmeasurable MALT lymphoma, Mantle Cell Lymphoma (MCL) and Follicular lymphoma for cohort 3
- •Known CD20 negative status at last biopsy done (Biopsy at relapse/progression is mandatory)
- •Central nervous system or meningeal involvement by lymphoma
- •Prior history of Progressive Multifocal Leukoencephalopathy (PML)
- •Documented infection with HIV
- •Active Hepatitis B (HB) (positive Hepatitis B surface antigen (Ag-HBs) OR positive serology to hepatitis B (positive Ag-HBs or Hepatitis B core antibody (anti-HBc) or Polymerisation Chain Reaction (PCR) for viral DNA of HBV) Active Hepatitis C (HC) infection (patients with positive HCV serology (anti-HCV) are eligible only if PCR is negative from known HCV RNA)
- •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) before inclusion, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to first administration of study drug
- •Active immune-related disease criteria
- •Left Ventricular Ejection Fraction (LVEF) < 45% as determined by echocardiography or multiple uptake gated acquisition (MUGA) scan
- •Any serious active disease or co-morbid medical condition (such as New York Heart Association Class III or IV cardiac disease, severe arrhythmia, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including uncontrolled obstructive pulmonary disease and history of bronchospasm or other according to investigator's decision)
- •Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
- •Any of the following laboratory abnormalities:
- •Hemoglobin < 9 g/dL
- •Absolute neutrophil count (ANC) < 1,000 cells/mm3 (1.0 G/L) unless due to lymphoma
- •Platelet count < 75,000/mm3 (75 x 109/L) unless due to lymphoma
- •Serum glutamic-oxaloacetic transaminase (SGOT) / Aspartate Transaminase (AST) or Serum Glutamic-Pyruvate Transferase (SGPT) / Alanine Transaminase (ALT) 3.0 x upper limit of normal (ULN) unless disease involvement
- •Serum total bilirubin > 2.0 mg/dL (34 μmol/L), except if disease related or in case of Gilbert syndrome
- •Calculated creatinine clearance (Cockcroft-Gault formula or MDRD) of < 50 mL /min
- •International normalized ratio (INR) ≤ 1.5 x ULN for patients not receiving therapeutic anticoagulation
- •Partial thromboplastin time (PTT) or activated PTT (aPTT) > 1.5 x ULN
- •Prior history of malignancies other than lymphoma unless the subject has been free of the disease for ≥ 3 years. Exceptions will be allowed for patients with non-melanoma skin tumors (basal cell or squamous cell carcinoma of the skin) or any surgically removed stage 0 (in situ) carcinoma
- •Any serious medical condition, laboratory abnormality (other than mentioned above), or psychiatric illness that would prevent the subject from signing the informed consent form
- •Contraindication to any drug contained in the study treatment regimen
- •Previous treatment with obinutuzumab, atezolizumab or venetoclax
- •Use of any standard or experimental anti-cancer drug therapy within 28 days prior to first administration of study drug
- •Use of warfarin prior to first administration of study drug and throughout all treatment period (because of potential drug-drug interactions that may potentially increase the exposure of warfarin)
- •Patients taking corticosteroids within 4 weeks prior to first administration of study drug, unless administered at a cumulated dose equivalent to ≤ 3.5mg/kg (within these 4 weeks).
- •Use of the following agents prior to first administration of study drug: Strong and moderate CYP3A inhibitors (including grapefruit juice); Strong and moderate CYP3A inducers
- •Pregnant or lactating females
- •Person deprived of his/her liberty by a judicial or administrative decision
- •Adult person under legal protection
- •Person hospitalized without consent
- •Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness
研究组 & 干预措施
Experimental
Experimental
Combination of venetoclax, atezolizumab and obinutuzumab
干预措施: Atezolizumab (Drug)
Experimental
Experimental
Combination of venetoclax, atezolizumab and obinutuzumab
干预措施: Obinutuzumab (Drug)
Experimental
Experimental
Combination of venetoclax, atezolizumab and obinutuzumab
干预措施: Venetoclax (Drug)
结局指标
主要结局
FL and DLBCL cohorts : Overall Metabolic Response Rate (OMRR) at the end of induction
时间窗: 8 months (8 cycles)
Assessment of disease response according to Lugano 2014
for iNHL cohort : Overall Response Rate (ORR) at the end of induction
时间窗: 8 months (8 cycles)
Assessment of disease response according to Lugano 2014
次要结局
- for FL and DLBCL cohorts : OMRR(4 months, 18 months)
- Best response(18 months)
- for iNHL cohort : ORR(4 months, 18 months)
- Overall Survival (OS)(4 years)
- Duration of Response (DR)(4 years)
- Progression Free Survival (PFS)(4 years)
研究者
研究点 (25)
Loading locations...
相似试验
进行中（未招募）
2 期
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/RearrangementsIntrahepatic CholangiocarcinomaNCT05174650Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest27
进行中（未招募）
2 期
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown PrimaryCancerNCT06754501M.D. Anderson Cancer Center4
已完成
2 期
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of Head and NeckNCT04665843Hoffmann-La Roche123
已完成
2 期
Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and NeckHead and Neck NeoplasmsNCT03818061Centre Leon Berard33
已完成
2 期
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionGastroesophageal Junction AdenocarcinomaGastric CancerNCT04661150Hoffmann-La Roche42